Wien, 28 - Repository of the LBI-HTA - Ludwig Boltzmann Gesellschaft

Radiofrequenzablation bei benignen und malignen Vera¨nderungen endokriner OrganeAuthor, year, referencenumberBaek (2010) [16] Deandra (2008) [24] Spieza (2009) [3]Drop-out rateOutcomeRFA: n/aobservation 0 (= 0%)0 (= 0%) 42 (= 44.7%)EfficacySymptom scorescore: 10cm visual analogue score to rate pressuresymptoms (scale not described)enrolment:observation : O/ 3.13 ±1.51 (range 0-6)RFA: O/ 3.33 ±0.9 (range 2-5)after 6 months:observation : O/ 3.4 ±1.72 (range 1-7); p = 0.21 4RFA: O/ 1.00 ±0.76 (range 0-2); p = 0.001 5score: 10-point visual analogue score to rate pressuresymptoms (scale not described)enrolment:O/ 6.1 ±1.4after 6 monthsO/ 2.2 ±1.9; p < 0.0001score: sum of single scores (pressure symptoms, difficultyin swallowing, aesthetic complaint); rangingfrom 0-6 (0=no symptoms, 6=worst symptoms)enrolment:O/ 3.4±0.2after 12 months:O/ 0.3±0.08; p < 0.001complete disappearance of all symptoms: 88.3%Cosmetic graderecorded by physician (1= no palpable mass, 4= easilyvisible mass)enrolment:observation : O/ 3.47 ±0.64 (range 2-4)RFA: O/ 3.6 ±0.51 (range 3-4)after 6 months:observation : O/ 3.6 ±0.63 (range 2-4); p = 0.16 6RFA: O/ 1.53 ±0.52 (range 1-2); p = 0.001 7n/an/a, see above4 Refers to symptom score of the observation group at 6 months follow-up compared to enrolment5 Refers to symptom score of the RFA group at 6 months follow-up compared to enrolment6 Refers to cosmetic grade of the observation group at 6 months follow-up compared to enrolment7 Refers to cosmetic grade of the RFA group at 6 months follow-up compared to enrolment22 LBI-HTA | 2012